Short radiation plus chemo for stage II–III rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of rectal adenocarcinoma (rectal cancer type) on biopsy
- Your cancer is stage II (cT3, cN0) or stage III (cT1-3, cN1-3) based on an MRI
- Your scans show no spread to other organs (no metastases)
- Your rectal tumor can be treated with surgery (it is considered resectable)
- Your body can handle treatment: energy level is decent (KPS ≥70 or ECOG 0–2) and blood counts are high enough (neutrophils, hemoglobin, platelets)
- Your liver tests are not too elevated, and if you can become pregnant you have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.